CareDx Rallies as Medicare Finalizes Transplant Testing Coverage
A reimbursement question that had hung over the stock for a year resolved in the company’s favor. Shares closed up about 35%. The policy affirms Medicare coverage for CareDx’s transplant surveillance tests in kidney, heart, and lung.
CareDx (Nasdaq: CDNA) shares closed up about 35% on Thursday after Medicare finalized a Local Coverage Determination affirming coverage for the company’s molecular tests that monitor transplant patients for signs of organ rejection. The decision resolved a question that had shadowed the stock for a year.
What the Policy Covers
The final policy, published July 16 and effective August 30, sets Medicare surveillance-testing coverage across CareDx’s three transplant franchises. It covers AlloSure Kidney for up to six tests in the first year after transplant and four per year in years two and three. For heart, it maintains coverage of AlloMap and AlloSure Heart, including their use in combination, at up to 12 tests in the first year. For lung, it covers AlloSure Lung at up to 12 first-year tests. For-cause testing, used when rejection is clinically suspected, is unchanged.
Why the Market Moved
The size of the reaction reflected relief more than expansion. A draft version of the policy, released in July 2025, had raised the prospect that Medicare might tighten how often these surveillance tests could be billed, a real risk for a company whose core revenue comes from repeat molecular testing. The final policy instead affirmed coverage at frequencies at or above current use. CareDx says kidney patients today average about three to four tests in the first year, below the six the policy allows. Removing that overhang, rather than adding new volume, is what repriced the shares.
A Business Already Growing
The clarity lands on a business that was already accelerating. First-quarter revenue rose 39% to $118 million, testing services revenue grew 48%, and the company posted GAAP net income of $3 million against a loss a year earlier. CareDx raised its full-year 2026 revenue guidance to a range of $447 million to $465 million. On July 1 it closed its acquisition of Naveris, whose NavDx is the only Medicare-covered test for molecular residual disease in HPV-driven head and neck and anal cancers, extending CareDx into specialty oncology and, by the company’s estimate, expanding its addressable market beyond $12 billion. Naveris consolidates into results starting in the third quarter.
For a company built on recurring diagnostic testing, reimbursement clarity is foundational, and Thursday’s move shows how much the market had discounted the risk that it might not arrive. A single-session gain of that size also sets a higher bar. The next test is CareDx’s second-quarter results, due July 30, which will show whether the underlying growth keeps pace with a stock that just repriced sharply on removed risk.
For informational purposes only. Not investment advice or a recommendation to buy or sell any security. Company forward-looking statements, including revenue guidance, are those of the company and are subject to the risks described in its SEC filings.
